22nd Century Group Inc (XXII)

0.93
AMEX : Health Care
Prev Close 0.94
Day Low/High 0.90 / 0.96
52 Wk Low/High 0.71 / 1.71
Avg Volume 1.09M
Exchange AMEX
Shares Outstanding 90.70M
Market Cap 85.26M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

22nd Century's Very Low Nicotine Cigarettes Significantly Reduce Withdrawal And Craving Symptoms In Vulnerable Population Groups

22nd Century's Very Low Nicotine Cigarettes Significantly Reduce Withdrawal And Craving Symptoms In Vulnerable Population Groups

22nd Century Group, Inc. (NYSE MKT: XXII), a leader in tobacco harm reduction, announced today that scientists from the University of Vermont Center on Tobacco Regulatory Science, Brown University, Johns Hopkins University,...

22nd Century Group Announces Closing Of $11.4 Million Above-Market Registered Direct Offering

22nd Century Group Announces Closing Of $11.4 Million Above-Market Registered Direct Offering

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced that the Company closed today a registered direct stock offering with one existing institutional...

22nd Century Group Announces Above-Market Offering For $11.4 Million

22nd Century Group Announces Above-Market Offering For $11.4 Million

22nd Century Group, Inc. (NYSE MKT:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Company entered into an agreement, dated October 14, 2016, with one...

22nd Century Very Low Nicotine Cigarettes Could Reduce U.S. Smoking Rates By More Than 75%

22nd Century Very Low Nicotine Cigarettes Could Reduce U.S. Smoking Rates By More Than 75%

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that a group of leading scientists from the United States and New Zealand have published a...

Phase III Clinical Trial With 22nd Century's Very Low Nicotine Cigarettes Names Ten Major Research Institutions As Study Locations

Phase III Clinical Trial With 22nd Century's Very Low Nicotine Cigarettes Names Ten Major Research Institutions As Study Locations

22nd Century Group, Inc. (NYSE MKT:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that an update has been issued on the pivotal Phase III study entitled "Strategies...

22nd Century Announces Expiration Of 2,250,000 Crede Warrants

22nd Century Announces Expiration Of 2,250,000 Crede Warrants

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that warrants previously issued by the Company to Crede CG III, Ltd.

Overwhelming Physician And Consumer Support Cited For 22nd Century's

Overwhelming Physician And Consumer Support Cited For 22nd Century's "X-22" Very Low Nicotine Smoking Cessation Product

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced results from two separate independent surveys showing that strong consumer demand mirrors...

22nd Century Announces Expansion Of Cannabis Research Program

22nd Century Announces Expansion Of Cannabis Research Program

22nd Century Group, Inc. (NYSE MKT:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction and cannabis research, announced today that the Company's wholly-owned subsidiary, Botanical Genetics...

22nd Century Group Files 2016 Second Quarter Report Announces Conference Call To Provide Business Update

22nd Century Group Files 2016 Second Quarter Report Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is a leader in tobacco harm reduction, today released the Company's second quarter 2016 financial results and announced that it will provide a...

22nd Century Group Announces $5.0 Million Registered Direct Offering At Market

22nd Century Group Announces $5.0 Million Registered Direct Offering At Market

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Company entered into an agreement as of July 24, 2016 with one existing...

Nicotine Reduction Strategy Is Championed By Growing Number Of Scientists And Public Health Experts

Nicotine Reduction Strategy Is Championed By Growing Number Of Scientists And Public Health Experts

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that in this month's issue of Tobacco Control , Drs.

World Health Organization Recommends

World Health Organization Recommends "Mandated Reductions In Nicotine To Minimally Addictive Levels"

22nd Century Group, Inc. (NYSE MKT:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the World Health Organization (WHO) Study Group on Tobacco Product Regulation...

22nd Century's Very Low Nicotine Cigarettes Reduce Smoking And Are Now Associated With Reduced Alcohol Use

22nd Century's Very Low Nicotine Cigarettes Reduce Smoking And Are Now Associated With Reduced Alcohol Use

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the journal Alcoholism: Clinical and Experimental Research has published a new...

New Study Shows Cigarettes Containing 22nd Century's Proprietary Tobacco Reduce Smoking And Toxicant Exposure

New Study Shows Cigarettes Containing 22nd Century's Proprietary Tobacco Reduce Smoking And Toxicant Exposure

22nd Century Group, Inc. (NYSE MKT:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Cancer Epidemiology Biomarkers and Prevention (CEBP) journal has published...

22nd Century's Proprietary SPECTRUM® Cigarettes Identified As Crucial Tool In Human Addiction Studies

22nd Century's Proprietary SPECTRUM® Cigarettes Identified As Crucial Tool In Human Addiction Studies

22nd Century Group, Inc. (NYSE MKT:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that scientists with The Centers for Disease Control and Prevention (CDC) published...

22nd Century Presents At Hofstra Northwell School Of Medicine; Reveals New Initiative To Engage Health Care Professionals

22nd Century Presents At Hofstra Northwell School Of Medicine; Reveals New Initiative To Engage Health Care Professionals

22nd Century Group, Inc. (NYSE MKT:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on May 26, 2016, Paul J.

22nd Century Launches MAGIC 0 Very Low Nicotine Cigarettes In France

22nd Century Launches MAGIC 0 Very Low Nicotine Cigarettes In France

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today the receipt of an initial purchase order for MAGIC 0 Very Low Nicotine cigarettes from...

Independent Phase II And III Clinical Studies On 22nd Century's Smoking Cessation Technology Highlighted On New Heracles Website

Independent Phase II And III Clinical Studies On 22nd Century's Smoking Cessation Technology Highlighted On New Heracles Website

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that 22nd Century has launched a new website at www.

22nd Century's New Research Cigarettes Are Available In Any Configuration And In Any Style Requested By Researchers. (Graphic: Business Wire)

22nd Century's New Research Cigarettes Are Available In Any Configuration And In Any Style Requested By Researchers. (Graphic: Business Wire)

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Company has launched a new line of Research Cigarettes with varying levels of...

22nd Century Launches Major New Initiative To Produce Medically-Important Marijuana Cannabinoids

22nd Century Launches Major New Initiative To Produce Medically-Important Marijuana Cannabinoids

22nd Century Group, Inc. (NYSE MKT:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction and cannabis research, announced today that it is launching a major new initiative to produce...

22nd Century Group Files 2016 First Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group Files 2016 First Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today the Company's first quarter 2016 financial results and will provide a business update...

22nd Century To Call For National Tobacco Harm Reduction Policy At Tobacco Merchants' Association National Conference

22nd Century To Call For National Tobacco Harm Reduction Policy At Tobacco Merchants' Association National Conference

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on Tuesday, May 10, 2016, Henry Sicignano, III, the Company's President and Chief...

22nd Century Comments On Frivolous Lawsuit Filed By Crede

22nd Century Comments On Frivolous Lawsuit Filed By Crede

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, has learned that Crede CG III, Ltd.

22nd Century Group To Utilize Revolutionary New Filter Technology From Strategic Supplier, Celanese Corporation

22nd Century Group To Utilize Revolutionary New Filter Technology From Strategic Supplier, Celanese Corporation

Clarence, New York - 22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company whose primary mission is to pioneer new technology to reduce the harm caused by smoking, announced today that it has entered into...

22nd Century Featured On The Cover Of Tobacco International Magazine

22nd Century Featured On The Cover Of Tobacco International Magazine

22nd Century Group, Inc. (NYSE MKT: XXII ), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that 22nd Century is the featured cover story of the newest issue of Tobacco...

Pioneer Of Altered Nicotine Tobacco To Give Keynote Address At 22nd Century Group's Annual Shareholder Meeting

Pioneer Of Altered Nicotine Tobacco To Give Keynote Address At 22nd Century Group's Annual Shareholder Meeting

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that Michael P.

22nd Century Announces Launch Of Very Low Nicotine MAGIC Cigarettes And Extreme Nicotine RED SUN Cigarettes In Australia

22nd Century Announces Launch Of Very Low Nicotine MAGIC Cigarettes And Extreme Nicotine RED SUN Cigarettes In Australia

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today the receipt of an initial purchase order from Australian tobacco distributor, Quay...

FDA Acknowledges Receipt Of 22nd Century's Very Low Nicotine Modified Risk Tobacco Product Application

FDA Acknowledges Receipt Of 22nd Century's Very Low Nicotine Modified Risk Tobacco Product Application

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that in a communication received by the Company, the Food and Drug Administration (FDA)...